Summary There is growing awareness that HIV infection is associated with low bone mass and fracture. DXA is a relatively scarce resource. Therefore, we evaluated two tools: peripheral DXA (pDXA) at the forearm and Fracture Risk Assessment Tool (FRAX®) to see which performed best at identifying men who should undergo DXA. In this setting, neither pDXA nor FRAX® showed good sensitivity and specificity for DXA. Purpose Infection with human immunodeficiency virus (HIV) is associated with an increased risk of low bone mineral density (BMD) and fractures. European guidance advocates screening using the FRAX® tool at diagnosis, on initiation of antiretroviral therapy and biannually thereafter in order to decide the need for DXA scanning. This cross-sectional study evaluates the performance of FRAX® and compares its sensitivity and specificity with that of another screening tool, peripheral forearm DXA (pDXA). Methods HIV-infected men with varying exposure to antiretroviral therapies were recruited. FRAX® scores were calculated for all participants and everybody underwent pDXA scanning. Femoral neck and lumbar spine BMD was acquired on a Hologic QDR machine by an assessor blinded to the results of the FRAX® and pDXA.
Results One hundred and sixty-eight men (median age 45 years) were recruited with a median duration since HIV diagnosis of 74 months. In total, 21 % of subjects had either osteoporosis (aged ≥50 years) or BMD lower than expected for age (aged <50 years), according to axial DXA. Using a pDXA screening threshold of T≤−0.9, sensitivity was high (91 %) in defining those with the worst BMD on axial DXA but with poorer specificity (33 %). Alternately, using a threshold of T≤−2.7 reduced sensitivity (34 %) with an increase in specificity (91 %). FRAX® with HIV included as a secondary risk factor had poor sensitivity (31 %) and specificity (74 %) for detecting those with the poorest BMD on axial DXA. Conclusion In this setting, neither pDXA scanning nor FRAX® was sensitive and specific for low bone mass on DXA and neither was performance much improved by using both screening tools. Prospective studies with fracture as an outcome are required in HIV.
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Background HIV is a global pandemic, affecting an estimated 35 million people worldwide. The majority of people infected with HIV are in Sub-Saharan Africa and other countries that are economically deprived. Untreated, HIV causes severe immunodeficiency and susceptibility to opportunistic infections and malignancies. However, the advent of antiretroviral therapies used in combination (cART) has produced dramatic improvement in the survival rates of people infected by HIV, and the life expectancy of treated subjects is now thought to have normalised [1] . However, as cART-treated patients increase in number, there has been growing recognition of the burden of non-AIDS morbidities including low bone mass and fractures [2] [3] [4] [5] [6] . An estimated 60 % of HIV-infected patients have osteopenia, and 10-15 % have osteoporosis [7] . Given its ubiquity, HIV could become a major cause of secondary osteoporosis and cost-effective strategies for identification and treatment of those at risk are required.
The World Health Organisation (WHO) defined osteoporosis on the basis of BMD measured at the lumbar spine and femoral neck using dual-energy X-ray absorptiometry (DXA) [8] . However, DXA is a relatively scarce resource, especially in resource-poor countries. European and British HIV Association guidelines [9, 10] recommend that HIV-infected patients aged >40 years should undergo regular risk assessment for low bone mass. The tool advocated is the Fracture Risk Assessment Tool (FRAX®) algorithm [11] which the guidelines have suggested can be used to define those who should undergo axial BMD assessment. The guidelines also recommend that physicians should consider using HIV as a 'secondary cause of osteoporosis' in the FRAX® algorithm. To date, use of FRAX® in HIV-infected populations has not been validated in practice and indeed, the results of two studies have suggested that FRAX® had poor sensitivity for BMD [12, 13] .
Peripheral DXA (pDXA) is a screening tool for osteoporosis, which is portable, involves very low levels of radiation and correlates well with BMD at other sites [14] . In other populations, it has been shown to be an effective screening tool and a good predictor of hip fracture [15] . However, it has not been evaluated in HIV patients. The aim of this investigation was to compare the utility of FRAX® with that of pDXA at the distal forearm in stratifying those patients who should undergo gold-standard DXA.
Methods
A consecutive cross-sectional sample of attendees at a UK Teaching Hospital HIV outpatient clinic was recruited MayAugust 2008; the study design and participant demographic has been previously published [16] . Patients were eligible if they were male, aged ≥18 years and had been diagnosed with HIV infection. Patients were excluded if they were unable to give written, informed consent or were current participators in other research studies and if they had undergone diagnostic DXA scanning within the last 12 months. Patients were purposively sampled to represent a range of exposures to cART, including: cART naïve; a group recently exposed for the first time to cART (<3 years) and those exposed to longer-term cART.
Participants completed a questionnaire for FRAX® calculation (personal and family history of fracture, smoking and alcohol use, exposure to oral glucocorticoids, hypogonadism, renal and/or liver impairment). Subjects gave permission for extraction of demographic, HIV parameters, cART regimen and validation of comorbidities from the department database and clinic notes. BMD was measured at the non-dominant forearm using pDXA (PIXI, Lunar Corp., Madison, WI, USA) with version 2.2 software using the standardised region of interest of the distal one third of the forearm. DXA scans of the lumbar spine and femoral neck were acquired using a Hologic QDR 4500C (Hologic, Inc., Waltham, MA, USA) by an assessor blinded to the results of the FRAX® and pDXA. For subjects aged ≥50 years, BMD was evaluated according to WHO guidance using T scores at the thresholds: T score >−1.0 for normal BMD, T score ≤−1.0 and >−2.5 for osteopenia and T score ≤−2.5 for osteoporosis. Given the demographic of HIV-infected subjects worldwide, for subjects aged <50 years, age-adjusted Z scores were calculated. Lower than expected bone mass for those aged <50 years was defined by a Z score ≤−2.0, and a Z score >−2.0 defined a bone mass within the expected range for age.
The study was approved by the Northern and Yorkshire Research Ethics Committee, UK (Ref: 08/H0903/13). All participants provided written, informed consent.
Statistical analysis
Data were analysed in SPSS® version 19 for Macintosh. Correlations between the different BMD measurements were measured using Pearson's correlation coefficients. The gold-standard low bone mass was a diagnosis of osteoporosis (aged ≥50 years) or BMD lower than expected for age (aged <50 years) on the Hologic DXA at either the femoral neck or the lumbar spine. The optimum pDXA forearm T score threshold for discriminating osteoporosis or BMD lower than expected for age at either femoral neck or the lumbar spine was assessed using receiver operator characteristic curves (ROC). FRAX® scores were computed for 10-year risk of any osteoporotic fracture and 10-year risk of a hip fracture for all study participants and then recalculated using HIV as a secondary cause of osteoporosis. The results were translated into ≥7.5 or <7.5 % 10-year risk of major osteoporotic fracture in addition to the National Osteoporosis Guideline Group (NOGG) intervention thresholds of low, intermediate (scan) and high (treat) risk [11] . The discriminatory capabilities of each of pDXA at defined thresholds and FRAX®, with and without HIV as a secondary risk factor, were compared.
Results
One hundred and sixty-eight HIV-infected eligible men were recruited. The median age of participants was 45 (interquartile range (IQR) 38-51, range 20-85) years, 97 % were Caucasian and 96 % acquired HIV through sexual transmission (mostly men who have sex with men (MSM)) ( Table 1 , adapted from [16] ). These characteristics were not significantly different from those of the entire cohort of outpatient attendees at this centre (data not shown). The mean body mass index of participants was 25 kg/m 2 (95 % confidence interval 24.5-25.7), 45 % were current smokers, 31 % consumed more than 21 units of alcohol/week and 6 % had been diagnosed with or treated for hypogonadism.
At study entry, the mean time from participants' diagnosis with HIV infection was 74 months (IQR 34-149). Thirtyseven subjects were cART naïve; 46 had been exposed to cART recently (<3 years) and 85 had received longer-term cART (median duration 157 weeks (IQR 4-544)). Twenty seven percent were taking cART that included a protease inhibitor, 42 % were taking a non-nucleoside reverse transcriptase inhibitor and 45 % were receiving the nucleotide reverse transcriptase inhibitor tenofovir. Four percent of participants had a CD4 count <200 cells/mm 3 , and 70 % had an undetectable viral load (<40 copies/mL). According to the gold-standard axial DXA, 21 % of study participants were osteoporotic or had lower than expected BMD for age at the lumbar spine (nobody at the femoral neck).
Peripheral DXA of the non-dominant forearm Forearm BMD measured at the non-dominant forearm with pDXA was highly significantly correlated with BMD at all sites measured using the Hologic DXA (p<0.0001). The correlation coefficients were highest between pDXA and BMD at the hip and forearm: total hip (correlation coefficient 0.624), femoral neck (correlation coefficient 0.624), nondominant forearm (correlation coefficient 0.695) and spine (correlation coefficient 0.485).
The area under curve (AUC) of the ROC for forearm T score to demonstrate osteoporosis/lower than expected BMD for age was 0.71. Using variable thresholds of T score for the pDXA, sensitivity and specificity for a diagnosis of osteoporosis/lower than expected BMD for age were assessed. A T score threshold ≤−0.9 on pDXA resulted in a sensitivity for detection of osteoporosis/lower than expected BMD for age of 91 % (32/35) with a specificity of 33 % (44/133). The positive predictive value (PPV) was 26 % (32/121). Only three subjects with osteoporosis/lower than expected BMD for age would not have been detected by pDXA, giving a negative predictive value (NPV) of 94 % (44/47). Alternately, a threshold of ≤−2.7 resulted in a higher specificity of 91 % (121/133) at the expense of a lower sensitivity of 34 % (12/35), with a PPV of 50 % (12/24) and a NPV of 84 % (121/144).
FRAX® scores
FRAX® scores were computed (with and without HIV as a secondary risk factor) for 10-year risk of any osteoporotic fracture and 10-year risk of a hip fracture for all study participants. The sensitivity and specificity for predicting those with low bone mass and normal BMD using the NOGG intervention threshold (intermediate and high) were compared ( Table 2 ). Addition of HIV as a secondary cause improved sensitivity of the FRAX® scores as a screening tool to identify osteoporosis/lower than expected BMD for age from 23 to 31 %. However, this change resulted in lower specificity of FRAX® to correctly identify those with normal BMD from 88 % (98/111) down to 74 % (82/111). The AUC of the ROC for 10-year major osteoporotic fracture risk to identify osteoporosis/lower BMD than expected for age was lower than the pDXA ROC AUC, 0.55 and 0.55 with and without HIV infection as a secondary risk factor and 0.59 and 0.61 for hip fracture risk. The ROC-derived threshold of ≥7.5 % 10-year risk of any major osteoporotic fracture using HIV as a secondary risk factor would identify similar rates of osteoporosis/lower than expected BMD for age as the NOGG intervention threshold (using HIV as a secondary risk factor), with a sensitivity of 31 % (11/35) but with a higher specificity to identify those with normal BMD of 87 % (97/111), (Fig. 1 ). Figure 1 compares the use of both FRAX® scores and pDXA to identify those individuals with osteoporosis/lower than expected BMD for age by axial DXA. Using the high sensitivity, high NPV forearm pDXA stratification threshold of T≤−0.9, of the 133 men without osteoporosis/low BMD for age, 44 (33 %) would have avoided axial-DXA scans; however, 71/111 (64 %) men with normal BMD would be scanned. These seventy-one men who would be sent for DXA after a 'false positive' pDXA could be reduced if FRAX® was applied as 61/71 (86 %) of these would have had a reassuring FRAX® score.
FRAX® and BMD
Interestingly, if the ≥7.5 % 10-year major fracture FRAX® score was used in the risk assessment in addition to pDXA, the number of men diagnosed with low bone mass would remain unchanged at 11 people with osteoporosis/ lower than expected BMD for age. The three individuals with osteoporosis/lower than expected BMD for age 'missed' by pDXA would not have been identified by FRAX® score of ≥7.5 %.
Discussion
We present the first study to evaluate pDXA as a pre-screening tool among HIV-infected men for defining those who should have gold-standard axial DXA and compare its utility with that of the FRAX® algorithm. We found that neither tool performed optimally on an individual level or when used together.
A threshold of T score ≤−0.9 on pDXA would be more sensitive than FRAX® for osteoporosis/lower than expected BMD for age but would result in more individuals having an axial DXA scan and falsely reassure 9 % of those with the worst bone health. The 91 % sensitivity is particularly noteworthy given that none of the 35 subjects with osteoporosis/lower than expected BMD for age were affected at the femoral neck. Since the relative proportion of cortical and trabecular bones in the vertebrae is different from that in the distal forearm and femoral neck, it is reassuring that only 3/35 of those with vertebral osteoporosis would have been 'missed' screening with pDXA. As suggested by EACS, FRAX® has optimal sensitivity when HIV is included as a secondary risk factor but, even then, its use results in considerably fewer gold-standard scans at a cost of falsely reassuring 69 % of those with osteoporosis/lower than expected BMD for age.
We, and others, have shown that pDXA correlated well with DXA, particularly at appendicular sites [15] . The Results of a 2×2 contingency analysis to evaluate the sensitivity and specificity of the Fracture Risk Assessment Tool (FRAX®) algorithm computed on the basis of classic risk factors (CRFs) alone and re-computed considering HIV infection as a secondary cause of low bone mass. Dual-energy X-ray absorptiometry (DXA). IT intervention threshold (defined by the National Osteoporosis Guideline Group) *T score <−2.5 (aged ≥50 years); **Z score ≤−2.0 (aged <50 years); *** T score >−1.0 (age ≥50 years) or Z score >−2.0 (<50 years)
advantages of pDXA include its speed, cheapness and portability combined with very low doses of radiation. However, our results suggest that with this performance, its use will not save the costs of many gold-standard scans. The FRAX® tool and other fracture risk assessment tools have shifted a paradigm in osteoporosis management. Previously, risk assessment was based on the comparison of an individual's BMD with the young adult mean in order to define those at highest risk of fracture but absolute fracture risk was not quantified and considerable numbers of people sustained osteoporotic fractures with 'normal' BMD. Using the FRAX® tool allows a clinician to weigh up risk factors as they apply to an individual in order to define those who can be reassured, those who have intermediate risk and should attend for DXA scanning and those for whom the absolute fracture risk is sufficiently high that intervention is indicated. FRAX® has been validated in many populations but not for those aged <40 years and nor has its validity been established in HIV populations. Validation in HIV has been hindered by the fact that many of the HIV-infected patients worldwide are still relatively young (the cohort studied here have a median age of 45 years), and the rates of osteoporotic fracture in HIV patients have not yet therefore been quantified. HIV patients may be at relatively higher risk of osteoporotic fracture given that they have multiple coexisting pathologies and therapies with complex effects on bone health. Indeed, there is a growing body of evidence to suggest that this is the case [2] [3] [4] [5] [6] , and the results of the largest of these studies suggested that crude rates of all fractures may be as much as doubled in the HIV cases as compared with uninfected controls [2] . However, until the fracture risk levels in HIV are established, the results of this study, along with those of others [12, 13] , suggest that FRAX® does not perform well in identifying those who should have the gold-standard test for osteoporosis.
The results of this study need to be considered alongside a number of limitations. The population studied here was typical of those attending this centre: male, Caucasian and mostly infected through sexual transmission. At many centres, this gender and transmission demographic would be atypical and it may be that the results presented here are not generalisable to more heterogeneous HIV populations and/or women with HIV. The age range in this study was wide: 20-85 years but 29 % were aged <40 years. As stated, many of those infected with HIV worldwide are still aged <50 years. Of course, WHO T scores were defined historically to differentiate postmenopausal women and men aged ≥50 years at highest risk of osteoporotic fracture. As such, BMD measurements for men aged <50 years cannot be used to diagnose individuals with either osteoporosis or osteopenia. In clinical practice however, HIV physicians need to make treatment decisions in younger men with HIV and are using Z score thresholds of ≤−2.0 for these purposes [10] . Given the limitations of the available evidence for the prevention of osteoporotic fracture in these patients, European and British guidance has been drawn up to assist practitioners managing 'real life' patients and have recommended the use of FRAX® to decide upon the necessity for gold-standard DXA assessment. To test this advice, we have utilised Z score thresholds to define those aged <50 years with a BMD below the expected range for age to enhance our power for showing that FRAX® and pDXA did/did not perform as good screening tools to decide upon the allocation of DXA both in those aged ≥50 years and those aged <50 years. Clearly, those with lower Z scores on DXA may have completely normal bone health, and we do not intend to imply that those with Z scores ≤−2.0 in this study have 'osteoporosis', but we chose to analyse and present our data this way in order to test the value of using screening tools to differentiate those who might have the poorest bone health, whatever their age.
In summary, this study suggests that using a threshold of T≤−0.9, pDXA has better sensitivity for osteoporosis/ lower than expected for age BMD than FRAX® but this is achieved at the cost of low specificity. Clearly, the true performance of these tools can only be assessed with prospective trials in which fracture is the outcome. However, for now, clinicians should consider DXA for those HIV patients with one or more risk factors for low BMD including age.
